Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates.

[1]  M. Wang,et al.  A model for familial exudative vitreoretinopathy caused by LPR5 mutations. , 2008, Human molecular genetics.

[2]  G. Hansen,et al.  PTH Stimulates Bone Formation in Mice Deficient in Lrp5 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  W. Cheung,et al.  A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene. , 2006, Bone.

[4]  A. Robling,et al.  The Wnt Co-receptor LRP5 Is Essential for Skeletal Mechanotransduction but Not for the Anabolic Bone Response to Parathyroid Hormone Treatment* , 2006, Journal of Biological Chemistry.

[5]  F. Keleştimur,et al.  Effects of 3 Years of Intravenous Pamidronate Treatment on Bone Markers and Bone Mineral Density in a Patient with Osteoporosis-Pseudoglioma Syndrome (OPPG) , 2006, Journal of pediatric endocrinology & metabolism : JPEM.

[6]  L. Dimeglio,et al.  Two‐Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  F. Grill,et al.  The osteoporosis pseudoglioma syndrome. Update and report on two affected siblings , 2006, Pediatric Radiology.

[8]  R. Jilka,et al.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.

[9]  Minrong Ai,et al.  Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. , 2005, American journal of human genetics.

[10]  M. Gillespie,et al.  Effects of parathyroid hormone on Wnt signaling pathway in bone , 2005, Journal of cellular biochemistry.

[11]  T. Tahira,et al.  Complexity of the genotype–phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes , 2005, Human mutation.

[12]  D. Lacombe,et al.  LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. , 2005, Joint, bone, spine : revue du rhumatisme.

[13]  O. Mäkitie,et al.  Heterozygous Mutations in the LDL Receptor‐Related Protein 5 (LRP5) Gene Are Associated With Primary Osteoporosis in Children , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Daniel L. Koller,et al.  Contribution of the LRP5 Gene to Normal Variation in Peak BMD in Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  M. Rubin,et al.  Parathyroid hormone as an anabolic therapy for women and men. , 2005, Journal of endocrinological investigation.

[16]  M. Trese,et al.  Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. , 2004, American journal of human genetics.

[17]  A. Uitterlinden,et al.  Influence of LRP5 Polymorphisms on Normal Variation in BMD , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  C. Pérez-Cerdá,et al.  Propionic acidemia: mutation update and functional and structural effects of the variant alleles. , 2004, Molecular genetics and metabolism.

[19]  E. Dermitzakis,et al.  Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. , 2004, American journal of human genetics.

[20]  B. Ettinger,et al.  Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  Michael J Parker,et al.  Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. , 2004, American journal of human genetics.

[22]  N. Niikawa,et al.  LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density , 2004, Journal of Human Genetics.

[23]  D. Lev,et al.  Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. , 2003, The Israel Medical Association journal : IMAJ.

[24]  Jens Bollerslev,et al.  Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. , 2003, American journal of human genetics.

[25]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[26]  Mark L. Johnson,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[27]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[28]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[29]  T. Cundy,et al.  Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. , 2000, The Journal of pediatrics.

[30]  F. Glorieux,et al.  Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  I. Shah,et al.  Osteoporosis pseudoglioma syndrome. , 1999, Indian pediatrics.

[32]  R. Lindsay,et al.  Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis , 1997, The Lancet.

[33]  Mark L. Johnson,et al.  Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13) , 1997, American journal of human genetics.

[34]  E. Steichen‐Gersdorf,et al.  Persistent hyperplastic primary vitreous in a family with osteoporosis‐pseudoglioma syndrome , 1997, Clinical dysmorphology.

[35]  A. De Paepe,et al.  The osteoporosis pseudoglioma syndrome. , 1993, Journal belge de radiologie.

[36]  A. De Paepe,et al.  Osteoporosis-pseudoglioma syndrome. , 1993, American journal of medical genetics.

[37]  C. McDowell,et al.  Multiple fractures in a child: the osteoporosis pseudoglioma syndrome. A case report. , 1992, The Journal of bone and joint surgery. American volume.

[38]  L. Peltonen,et al.  Osteoporosis-pseudoglioma syndrome: clinical, morphological, and biochemical studies. , 1988, Journal of medical genetics.

[39]  M. Marafie,et al.  Osteoporosis-pseudoglioma syndrome with congenital heart disease: a new association. , 1988, Journal of medical genetics.

[40]  B. Dallapiccola,et al.  Osteoporosis-pseudoglioma syndrome: report of three affected sibs and an overview. , 1985, American journal of medical genetics.

[41]  C. Papadatos,et al.  Syndrome of osteoporosis with pseudoglioma. , 1982, Annales de genetique.

[42]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[43]  J. Dudgeon.  Familial exudative vitreo-retinopathy. , 1979, Transactions of the ophthalmological societies of the United Kingdom.

[44]  V. G. Criswick,et al.  Familial exudative vitreoretinopathy. , 1969, American journal of ophthalmology.